FDA Reprimands Snake Venom Seller For Pain Claims Amid Opioid Crisis
Nutra Pharma’s Nyloxin claims to relieve cancer pain and potentially help treat opioid addiction, among others, mark its products as unapproved new drugs, FDA asserts in a warning letter that reflects its homeopathic enforcement approach proposed in late 2017. “Health fraud scams like these are inexcusable,” says FDA Commissioner Scott Gottlieb.
You may also be interested in...
EPH Technologies apparently heeds FDA's warning, which also noted violative drug and disease claims for nasal sprays. EPH continued selling other supplements on 2 December, but the three that FDAcited in 18 November warning were not available.
FDA says Newton Laboratories sells unapproved Rx homeopathics because its products are labeled to treat diseases and conditions including allergies, chicken pox and “suicidal tendency.” Warning letter says firm also has repeatedly violated same GMPs across more than a decade of inspections.
FDA warns King Bio, three other homeopathic product marketers. In addition to GMP deficiencies, "we continue to see products labeled as homeopathic that are being marketed without approval for a wide array of diseases and conditions, from chronic pain to cancer,” says FDA Commissioner Gottlieb.